Related references
Note: Only part of the references are listed.COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options
Tomasz J. Guzik et al.
CARDIOVASCULAR RESEARCH (2020)
Early Short-Course Corticosteroids in Hospitalized Patients With COVID-19
Raef Fadel et al.
CLINICAL INFECTIOUS DISEASES (2020)
Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China
Chuan Qin et al.
CLINICAL INFECTIOUS DISEASES (2020)
Use of anakinra in severe COVID-19: A case report
Giovanni Filocamo et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2020)
Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease
Emanuele Pontali et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
Clinical and immunological features of severe and moderate coronavirus disease 2019
Guang Chen et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
Fei Zhou et al.
LANCET (2020)
Immunomodulation in COVID-19
Nicholas E. Ingraham et al.
LANCET RESPIRATORY MEDICINE (2020)
Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study
Sofia Ramiro et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19 The CoDEX Randomized Clinical Trial
Bruno M. Tomazini et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Anakinra for severe forms of COVID-19: a cohort study
Thomas Huet et al.
LANCET RHEUMATOLOGY (2020)
Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study
Giulio Cavalli et al.
LANCET RHEUMATOLOGY (2020)
Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome
Puja Mehta et al.
LANCET RHEUMATOLOGY (2020)
Inflammation and cardiovascular disease - Role of the interleukin-1 receptor antagonist
William F. Fearon et al.
CIRCULATION (2008)